QUOTED. 27 November 2019. Dan Rose.
LimFlow expects the US Food and Drug Administration to approve its percutaneous deep vein arterialization system for patients with advanced critical limb ischemia by the end of 2021. See what Lim Flow's CEO, Dan Rose, said about it here.
“The patients are, essentially, on the cusp of major limb amputation and we are keeping them with their legs and their wounds are fully healed which, in many ways, dramatically reduces the risk of a future amputation.” – Dan Rose, CEO, LimFlow
- Find out more: LimFlow On Target For 2021 US Launch Of Deep Vein Arterialization System
Click here for a free trial of Medtech Insight